AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway

Melanoma Research

Volumn 22, Issue 5, 2012, Pages 341-350

  Petti, Carlotta ^a,c   Vegetti, Claudia ^a   Molla, Alessandra ^a   Bersani, Ilaria ^a   Cleris, Loredana ^a   Mustard, Kirsty J ^b   Formelli, Franca ^a   Hardie, Grahame D ^b   Sensi, Marialuisa ^a   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c Australia   (Australia)

Author keywords

5 aminoimidazole 4 carboxamide ribonucleoside; adenosine monophosphate activated protein kinase; melanoma; phenformin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; B RAF KINASE; BETA GALACTOSIDASE; MITOGEN ACTIVATED PROTEIN KINASE; PHENFORMIN; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; XENOGRAFT;

AMINO ACID SEQUENCE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME ACTIVATORS; FEMALE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PHENFORMIN; PHOSPHORYLATION; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84866256417     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283544929     Document Type: Article

References (47)

1. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8:774-785. (Pubitemid 47462132)
2. Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003; 546:159-165. (Pubitemid 36782298)
3. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2:28.
4. Sakamoto K, Zarrinpashneh E, Budas GR, Pouleur AC, Dutta A, Prescott AR, et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 2006; 290:E780-E788.
5. Davies SP, Carling D, Hardie DG. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 1989; 186:123-128. (Pubitemid 20015134)
6. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003; 31:162-168. (Pubitemid 36241420)
7. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415:339-343. (Pubitemid 34087557)
8. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295. (Pubitemid 35373562)
9. Ruderman NB, Park H, Kaushik VK, Dean D, Constant S, Prentki M, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003; 178:435-442. (Pubitemid 36960435)
10. Chen ZP, McConell GK, Michell BJ, Snow RJ, Canny BJ, Kemp BE. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 2000; 279:E1202-E1206.
11. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004; 320:449-454. (Pubitemid 38798888)
12. Hardie DG. New roles for the LKB1-AMPK pathway. Curr Opin Cell Biol 2005; 17:167-173.
13. Wang W, Yang X, Lopez de Silanes I, Carling D, Gorospe M. Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem 2003; 278:27016-27023. (Pubitemid 36876855)
14. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-293. (Pubitemid 41350534)
15. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321:161-167. (Pubitemid 39055618)
16. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005; 280:39582-39593. (Pubitemid 41713917)
17. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33:237-247.
18. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKa energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009; 4:e4771.
19. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH. Activation of AMPactivated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 2011; 226:1915-1925.
20. Woodard J, Platanias LC. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 2010; 398:135-139.
21. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995; 229:558-565.
22. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51: 2420-2425. (Pubitemid 34827390)
23. Sakamoto K, Gö ransson O, Hardie DG, Alessi DR. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 2004; 287:E310-E317. (Pubitemid 38943898)
24. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996; 156:208-217. (Pubitemid 26006965)
25. Lupetti R, Sensi M, Mortarini R, Anichini A, Clemente C, Parmiani G. N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma. Melanoma Res 1994; 4:11-19. (Pubitemid 24127095)
26. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004; 23:5968-5977. (Pubitemid 39093541)
27. Hardie DG, Salt IP, Davies SP. Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. Methods Mol Biol 2000; 99:63-74.
28. Woods A, Cheung PC, Smith FC, Davison MD, Scott J, Beri RK, et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 1996; 271:10282-10290.
29. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277:25226-25232. (Pubitemid 34951829)
30. Sakamoto K, McCarthy A, Smith D, Green KA, Grahame Hardie D, Ashworth A, et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 2005; 24: 1810-1820. (Pubitemid 40769500)
31. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 2006; 66:6503-6511. (Pubitemid 44085604)
32. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001; 61:318-326. (Pubitemid 32095733)
33. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102:1555-1577.
34. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-1305. (Pubitemid 40813563)
35. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766-1777.
36. Del Barco S, Vazquez-Martin A, Cuf?́ S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917.
37. Andú jar-Plata P, Pi-Sunyer X, Laferrè re B. Metformin effects revisited. Diabetes Res Clin Pract 2012; 95:1-9.
38. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322-326.
39. Garrett CR, Hassabo HM, Bhadkamkar NA,Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012; 106:1374-1378.
40. Taubes G. Unraveling the obesity-cancer connection. Science 2012; 335:30-32.
41. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med 2011; 9:76.
42. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011; 2: e199-1-e199-10.
43. Fogarty S, Hardie DG. C-terminal phosphorylation of LKB1 is not required for regulation of AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest. J Biol Chem 2009; 284:77-84.
44. Guan TJ, Qin FJ, Du JH, Geng L, Zhang YY, Li M. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells. Acta Pharmacol Sin 2007; 28:1984-1990. (Pubitemid 350198343)
45. Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim J, et al. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside (AICAR). J Endocrinol 2011; 211:79-85.
46. Jose C, Hebert-Chatelain E, Bellance N, Larendra A, Su M, Nouette-Gaulain K, et al. AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta 2011; 1807:707-718.
47. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47:2150-2157.